Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
223 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ischemia - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Ischemia - Pipeline Review, H2 2015', provides an overview of the Ischemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ischemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ischemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ischemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 8 Global Markets Direct Report Coverage 8 Ischemia Overview 9 Therapeutics Development 10 Pipeline Products for Ischemia - Overview 10 Pipeline Products for Ischemia - Comparative Analysis 11 Ischemia - Therapeutics under Development by Companies 12 Ischemia - Therapeutics under Investigation by Universities/Institutes 16 Ischemia - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Ischemia - Products under Development by Companies 20 Ischemia - Products under Investigation by Universities/Institutes 24 Ischemia - Companies Involved in Therapeutics Development 25 Alize Pharma SAS 25 Amyndas Pharmaceuticals LLC 26 AnGes MG, Inc. 27 Apceth GmbH & Co. KG 28 Athersys, Inc. 29 Baxalta Incorporated 30 Caladrius Biosciences, Inc. 31 Cellmid Limited 32 CoDa Therapeutics, Inc. 33 CohBar, Inc. 34 Cynata Therapeutics Limited 35 DNAVEC Corporation 36 GlaxoSmithKline Plc 37 Hemostemix Ltd 38 IntelliCell BioSciences Inc. 39 Juventas Therapeutics, Inc. 40 Kasiak Research Private Limited 41 Lixte Biotechnology Holdings, Inc. 42 Mesoblast Limited 43 Miltenyi Biotec GmbH 44 Mirrx Therapeutics A/S 45 Multi Gene Vascular Systems Ltd 46 NoNO, Inc. 47 Nyken BV 48 Pathfinder Cell Therapy, Inc. 49 Pharmicell Co., Ltd. 50 Pluristem Therapeutics Inc. 51 Protagenic Therapeutics Inc. 52 ReNeuron Group Plc 53 Sihuan Pharmaceutical Holdings Group Ltd. 54 Stempeutics Research Private Limited 55 Targazyme, Inc. 56 Taxus Cardium Pharmaceuticals Group Inc. 57 TikoMed AB 58 U.S. Stem Cell, Inc. 59 Vericel Corporation 60 ViroMed Co., Ltd. 61 Ischemia - Therapeutics Assessment 62 Assessment by Monotherapy Products 62 Assessment by Target 63 Assessment by Mechanism of Action 66 Assessment by Route of Administration 68 Assessment by Molecule Type 70 Drug Profiles 72 AB-002 - Drug Profile 72 ACP-01 - Drug Profile 74 AdipoCell - Drug Profile 76 Alda-1 - Drug Profile 78 Alecmestencel-T - Drug Profile 79 alferminogene tadenovec - Drug Profile 80 AntimiR-199a - Drug Profile 82 ASCT-01 - Drug Profile 83 Autologous Vascular Cells Therapy - Drug Profile 84 AZP-531 - Drug Profile 85 beperminogene perplasmid - Drug Profile 87 bucillamine - Drug Profile 92 CD-52 - Drug Profile 93 Cell Therapy for Critical Limb Ischemia - Drug Profile 94 Cell Therapy for Ischemia - Drug Profile 95 Cell Therapy for Ischemia - Drug Profile 96 Cellgram for Severe Lower Limb Ischemia - Drug Profile 97 Cinepazide Mesylate - Drug Profile 98 CLBS-12 - Drug Profile 99 CMK-103 - Drug Profile 100 daprodustat - Drug Profile 101 DVC1-0101 - Drug Profile 103 EP-80317 - Drug Profile 105 Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile 106 Humanin - Drug Profile 107 ixmyelocel-T - Drug Profile 109 JVS-100 - Drug Profile 112 JVS-200 - Drug Profile 114 LB-100 - Drug Profile 115 LB-102 - Drug Profile 117 MicroRNA for Ischemia - Drug Profile 119 MPC-25IC - Drug Profile 120 MultiGeneAngio - Drug Profile 121 MultiStem - Drug Profile 123 NYK-1112 - Drug Profile 127 Oligonucleotide to Inhibit miRNA-26 for Ischemic Cardiovascular Disease - Drug Profile 128 Oligonucleotides for Immunology, Oncology, Infectious and Cardiovascular Disorders - Drug Profile 129 Pathfinder Cells - Drug Profile 130 Peptagon - Drug Profile 132 PLX-PAD - Drug Profile 133 PMC-6 - Drug Profile 137 Protein to Agonize LRP5 and LRP6 for Myocardial Infarction and Critical Limb Ischemia - Drug Profile 138 PT-00114 - Drug Profile 139 Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile 140 Recombinant Protein for Critical Limb Ischemia - Drug Profile 141 Recombinant Protein for Ischemia - Drug Profile 142 Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile 143 Refacell-CLI - Drug Profile 144 Rejuveinix - Drug Profile 145 ReN-009 - Drug Profile 146 Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 147 Small Molecules for Ischemia and Reperfusion Injury - Drug Profile 148 Small Molecules for Renal Failure and Renal Ischemia - Drug Profile 149 Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile 150 Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile 151 Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile 152 Stem Cell Therapy for Cardiovacular Diseases - Drug Profile 153 Stem Cell Therapy for Cardiovascular Disease - Drug Profile 154 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 156 Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 158 Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Drug Profile 159 Stempeucel - Drug Profile 160 Stromal Cell Therapy for Critical Limb Ischemia - Drug Profile 163 TM-700 - Drug Profile 164 TZ-101 - Drug Profile 165 VM-202 - Drug Profile 167 Ischemia - Recent Pipeline Updates 169 Ischemia - Dormant Projects 206 Ischemia - Discontinued Products 212 Ischemia - Product Development Milestones 213 Featured News & Press Releases 213 Appendix 218 Methodology 218 Coverage 218 Secondary Research 218 Primary Research 218 Expert Panel Validation 218 Contact Us 218 Disclaimer 219
List of Tables
Number of Products under Development for Ischemia, H2 2015 14 Number of Products under Development for Ischemia - Comparative Analysis, H2 2015 15 Number of Products under Development by Companies, H2 2015 17 Number of Products under Development by Companies, H2 2015 (Contd..1) 18 Number of Products under Development by Companies, H2 2015 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2015 20 Comparative Analysis by Late Stage Development, H2 2015 21 Comparative Analysis by Clinical Stage Development, H2 2015 22 Comparative Analysis by Early Stage Development, H2 2015 23 Products under Development by Companies, H2 2015 24 Products under Development by Companies, H2 2015 (Contd..1) 25 Products under Development by Companies, H2 2015 (Contd..2) 26 Products under Development by Companies, H2 2015 (Contd..3) 27 Products under Investigation by Universities/Institutes, H2 2015 28 Ischemia - Pipeline by Alize Pharma SAS, H2 2015 29 Ischemia - Pipeline by Amyndas Pharmaceuticals LLC, H2 2015 30 Ischemia - Pipeline by AnGes MG, Inc., H2 2015 31 Ischemia - Pipeline by Apceth GmbH & Co. KG, H2 2015 32 Ischemia - Pipeline by Athersys, Inc., H2 2015 33 Ischemia - Pipeline by Baxalta Incorporated, H2 2015 34 Ischemia - Pipeline by Caladrius Biosciences, Inc. , H2 2015 35 Ischemia - Pipeline by Cellmid Limited, H2 2015 36 Ischemia - Pipeline by CoDa Therapeutics, Inc., H2 2015 37 Ischemia - Pipeline by CohBar, Inc., H2 2015 38 Ischemia - Pipeline by Cynata Therapeutics Limited, H2 2015 39 Ischemia - Pipeline by DNAVEC Corporation, H2 2015 40 Ischemia - Pipeline by GlaxoSmithKline Plc, H2 2015 41 Ischemia - Pipeline by Hemostemix Ltd, H2 2015 42 Ischemia - Pipeline by IntelliCell BioSciences Inc., H2 2015 43 Ischemia - Pipeline by Juventas Therapeutics, Inc., H2 2015 44 Ischemia - Pipeline by Kasiak Research Private Limited, H2 2015 45 Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015 46 Ischemia - Pipeline by Mesoblast Limited, H2 2015 47 Ischemia - Pipeline by Miltenyi Biotec GmbH, H2 2015 48 Ischemia - Pipeline by Mirrx Therapeutics A/S, H2 2015 49 Ischemia - Pipeline by Multi Gene Vascular Systems Ltd, H2 2015 50 Ischemia - Pipeline by NoNO, Inc., H2 2015 51 Ischemia - Pipeline by Nyken BV, H2 2015 52 Ischemia - Pipeline by Pathfinder Cell Therapy, Inc., H2 2015 53 Ischemia - Pipeline by Pharmicell Co., Ltd., H2 2015 54 Ischemia - Pipeline by Pluristem Therapeutics Inc., H2 2015 55 Ischemia - Pipeline by Protagenic Therapeutics Inc., H2 2015 56 Ischemia - Pipeline by ReNeuron Group Plc, H2 2015 57 Ischemia - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2015 58 Ischemia - Pipeline by Stempeutics Research Private Limited, H2 2015 59 Ischemia - Pipeline by Targazyme, Inc., H2 2015 60 Ischemia - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2015 61 Ischemia - Pipeline by TikoMed AB, H2 2015 62 Ischemia - Pipeline by U.S. Stem Cell, Inc., H2 2015 63 Ischemia - Pipeline by Vericel Corporation, H2 2015 64 Ischemia - Pipeline by ViroMed Co., Ltd., H2 2015 65 Assessment by Monotherapy Products, H2 2015 66 Number of Products by Stage and Target, H2 2015 68 Number of Products by Stage and Mechanism of Action, H2 2015 71 Number of Products by Stage and Route of Administration, H2 2015 73 Number of Products by Stage and Molecule Type, H2 2015 75 Ischemia Therapeutics - Recent Pipeline Updates, H2 2015 173 Ischemia - Dormant Projects, H2 2015 210 Ischemia - Dormant Projects (Contd..1), H2 2015 211 Ischemia - Dormant Projects (Contd..2), H2 2015 212 Ischemia - Dormant Projects (Contd..3), H2 2015 213 Ischemia - Dormant Projects (Contd..4), H2 2015 214 Ischemia - Dormant Projects (Contd..5), H2 2015 215 Ischemia - Discontinued Products, H2 2015 216
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
